IL-17A inhibitor reimbursed for nr-axSpa Secukinumab (Cosentyx) has been listed on the PBS for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA). According to manufacturer, Novartis, secukinumab is the first interleukin-17A (IL-17A) ) inhibitor to be to be reimbursed in Australia for the treatment of active nr-axSpA. The PBS criteria state that to be ...
News in brief: Secukinumab on PBS for nr-axSpA; Cannabis not recommended for chronic pain; MTX action plans
31 Mar 2021